File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Metastatic pancreatic cancer: Are we making progress in treatment?

TitleMetastatic pancreatic cancer: Are we making progress in treatment?
Authors
Issue Date2012
Citation
Gastroenterology Research and Practice, 2012 How to Cite?
AbstractDevelopment of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival benefit. However, there were only marginal benefits in people with good performance status. Recently, the combination regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was found to achieve unprecedented survival benefit and has become the preferred option for patients with good clinical conditions. On the other hand, many biological agents have been combined with GEM, but only erlotinib was found to derive statistically significant survival advantage. However, the effect was too small to be appreciated clinically. The effort in development of targeted therapy in APC continues. This paper summarized key findings in the development of chemotherapy and targeted therapy for APC patients and discussed future directions in management. © 2012 Joanne Chiu and Thomas Yau.
Persistent Identifierhttp://hdl.handle.net/10722/200118
ISSN
2015 Impact Factor: 1.742
2015 SCImago Journal Rankings: 0.664
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChiu, Joanne-
dc.contributor.authorYau, Thomas-
dc.date.accessioned2014-07-26T23:11:09Z-
dc.date.available2014-07-26T23:11:09Z-
dc.date.issued2012-
dc.identifier.citationGastroenterology Research and Practice, 2012-
dc.identifier.issn1687-6121-
dc.identifier.urihttp://hdl.handle.net/10722/200118-
dc.description.abstractDevelopment of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival benefit. However, there were only marginal benefits in people with good performance status. Recently, the combination regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was found to achieve unprecedented survival benefit and has become the preferred option for patients with good clinical conditions. On the other hand, many biological agents have been combined with GEM, but only erlotinib was found to derive statistically significant survival advantage. However, the effect was too small to be appreciated clinically. The effort in development of targeted therapy in APC continues. This paper summarized key findings in the development of chemotherapy and targeted therapy for APC patients and discussed future directions in management. © 2012 Joanne Chiu and Thomas Yau.-
dc.languageeng-
dc.relation.ispartofGastroenterology Research and Practice-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleMetastatic pancreatic cancer: Are we making progress in treatment?-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1155/2012/898931-
dc.identifier.scopuseid_2-s2.0-84871384069-
dc.identifier.hkuros216945-
dc.identifier.eissn1687-630X-
dc.identifier.isiWOS:000312317200001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats